Ned Sharpless to continue where Scott Gottlieb left off at FDA
Sharpless pledged to continue the agency's work promoting innovation and competition while tackling problems like vaccine avoidance and marketing of unsafe and unproven health products.
NCI’s Norman Sharpless named as acting FDA commissioner to succeed Gottlieb
Sharpless, the director of the National Cancer Institute, was reportedly favored by HHS Secretary Alex Azar as outgoing Commissioner Scott Gottlieb's successor.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Who has the chops to succeed Scott Gottlieb as FDA commissioner?
Gottlieb, who is expected to step down in about a month, leaves behind a unique legacy and will likely be difficult to replace.